Product Image

Contributor Information

  • Name Roy Jefferis
  • Institute Absolute Antibody ; University of Birmingham

Tool Details

  • Tool name: Anti-CD19 [BU12] rAb
  • Alternate names: CD19 Molecule; B-Lymphocyte Surface Antigen B4; T-Cell Surface Antigen Leu-12; Differentiation Antigen CD19; CD19 Antigen; CVID3; B4
  • Clone: BU12
  • Tool type: Antibodies
  • Tool sub-type: Primary antibody
  • Class: Recombinant
  • Conjugate: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Application: FACS ; IHC ; IP
  • Description: CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. It is a single chain glycoprotein, present on the surface of normal and neoplastic B-cells. CD19 is expressed at an early stage by projenitor B-cells in bone marrow and during all stages of B-cell maturation. This antigen is lost upon terminal differentiation to plasma cells. CD19 is important for detecting both normal and neoplastic B-cells. CD19 is present on neoplasms arising from early B-cells (e.g. acute leukaemia of pre-B-cells) and more differentiated B-cell neoplasms (e.g. chronic Lymphocytic leukaemia and non-Hodgkin's lymphoma). Leukaemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen. The CD19 cytoplasmic domain binds tyrosine kinases and PI-3 kinase.
  • Immunogen: Human EB-4 Burkitt's lymphoma cell line
  • Isotype: IgG1
  • Research area: Immunology

  • For Research Use Only

Target Details

  • Target: CD19
  • Target background: CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. It is a single chain glycoprotein, present on the surface of normal and neoplastic B-cells. CD19 is expressed at an early stage by projenitor B-cells in bone marrow and during all stages of B-cell maturation. This antigen is lost upon terminal differentiation to plasma cells. CD19 is important for detecting both normal and neoplastic B-cells. CD19 is present on neoplasms arising from early B-cells (e.g. acute leukaemia of pre-B-cells) and more differentiated B-cell neoplasms (e.g. chronic Lymphocytic leukaemia and non-Hodgkin's lymphoma). Leukaemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen. The CD19 cytoplasmic domain binds tyrosine kinases and PI-3 kinase.

Application Details

  • Application: FACS ; IHC ; IP

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Storage buffer: PBS
  • Shipping conditions: Shipping at 4° C

Documentation

Related Tools

Product Image

Anti-porcine thermal-stable blood protein (TSBP) (90 kDa) [22E10/A5]

#156460
Product Image

Anti-DNA [m165-27]

#157825
Product Image

Anti-Skeletal Muscle Troponin I [skTrop I]

#151605

References

  • •  Original hybridoma first published in: Callard et al. 1992. J Immunol. 148(10):2983-7. PMID: 1374445.